Drug Profile

Research programme: respiratory disorder therapeutics - PARI Pharma

Alternative Names: Disodium Cromoglycate - PARI; DSCG - PARI Pharma; Levofloxacin VibrENT; Sodium cromoglicate - PARI Pharma

Latest Information Update: 16 Jul 2016

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator PARI Pharma GmbH
Class Benzopyrans; Chromones; Fluoroquinolones; Small molecules
Mechanism of Action DNA gyrase inhibitors; Mast cell stabilisers; Type II DNA topoisomerase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes - Rhinosinusitis

16 Jul 2016 No recent reports of development identified for preclinical development in Rhinosinusitis in Germany (Inhalation)
11 Sep 2013 Research programme: respiratory disorder therapeutics - PARI Pharma is available for licensing as of 11 Sep 2013.
26 Jan 2010 Preclinical trials in Asthma in Germany (Inhalation)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com